Trial Profile
Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria PfSPZ Vaccine and Sanaria PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Malaria vaccine live attenuated-Sanaria (Primary) ; Malaria vaccine live unattenuated-Sanaria (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanaria
- 12 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 12 Oct 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 25 Jul 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.